Hospitalized Cardiovascular Diseases in Neovascular Age-Related Macular Degeneration

The Degge Group, Ltd, Arlington, Virginia, USA.
Archives of ophthalmology (Impact Factor: 4.4). 09/2008; 126(9):1280-6. DOI: 10.1001/archopht.126.9.1280
Source: PubMed


To compare the incidence rate of hospitalized myocardial infarctions (MIs) and cerebrovascular accidents (CVAs) in subjects with and without neovascular age-related macular degeneration (AMD).
A retrospective database cohort study was performed in subjects with neovascular AMD and controls matched for age, sex, geography, and enrollment duration. Healthcare claims for the study period from January 1, 2002, to June 30, 2005, were used to identify subjects and outcomes. Incidence of hospitalized MI and CVA events and rate ratios adjusted for 11 risk factors were calculated.
In 7203 subjects with neovascular AMD and 20,208 controls, the rate of MI was 16.2 events per 1000 subjects with neovascular AMD and 23.1 events per 1000 controls. The adjusted rate ratio for MI was 0.58 (95% confidence interval, 0.48-0.72; P < .001) for subjects with neovascular AMD vs controls. The rate of CVA was 14.3 events per 1000 subjects with neovascular AMD and 22.1 events per 1000 controls. The adjusted rate ratio for CVA was 0.56 (95% confidence interval, 0.45-0.70; P < .001).
Rates of MI or CVA were significantly lower in subjects with neovascular AMD than in controls. These findings could not be explained by systematic differences in case selection, health care use, or comorbidities, although other possible biases cannot be ruled out.

Download full-text


Available from: Emily West Gower,
  • Source
    • "This retrospective and nonrandomized study found that systemic adverse events occurred in 7 of the 503 patients (1.4%) in the bevacizumab group and in 3 of the 199 patients in the ranibizumab group (1.5%); this was not a significant difference. The event rates that we observed are similar to previously reported findings (13-15). Although the 2 groups in our study differed with respect to age and concomitant diseases such as diabetes mellitus and dyslipidemia, they were similar in terms of systemic adverse events even after adjusting for these factors. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to compare the incidence of systemic adverse events in patients treated with intravitreal injections of bevacizumab or ranibizumab, and to evaluate whether compared to ranibizumab administration, bevacizumab constitutes a higher risk for systemic adverse events. A retrospective review was conducted for 916 consecutive patients treated with at least 1 intravitreal injection of bevacizumab or ranibizumab. Cox regression was performed to assess whether a variable had predictive value for occurrence of new systemic adverse events and to account for different follow-up times. A total of 702 patients were analyzed; 503 patients received bevacizumab alone, and 199 patients received ranibizumab alone. Systemic adverse events occurred in 10 of 702 patients (1.4%): 7 in the bevacizumab group (7/503; 1.4%) and 3 in the ranibizumab group (3/199; 1.5%). This difference was not statistically significant (Fisher's exact test, P = 0.573). Cox proportional hazards analysis of 4 models did not reveal a covariate that significantly changed the hazard for systemic adverse events. In conclusion, compared to ranibizumab, bevacizumab may not increase the risk of systemic adverse events in patients receiving intravitreal injections.
    Journal of Korean medical science 12/2012; 27(12):1580-5. DOI:10.3346/jkms.2012.27.12.1580 · 1.27 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Even moderate exposures of ambient light can impose a threat to human retina and the retinal pigment epithelium – under particular preconditions. Repetitive light-stress implicates reversible phototoxic damage thereby paving the way towards age related macular degeneration (AMD) via temporal summation. Aggravating and interacting prerequisites like genotype/complement factors, smoking, nanomaterials (NM) and obstructive sleep disorders (OSA) as well as other factors "reflective of nature and nurture" [97, 98] eventually impact on the severity of retinal light damage linked to possible formation and progression of AMD. Unter gewissen Voraussetzungen können mäßige, scheinbar nicht überdosierte Licht – Belastungen Schäden der Netzhaut verursachen. Genotyp/Komplement-System, Rauchen, Stoffwechsel-Störungen, möglicherweise auch Schlaf-Apnoe und "Nano-Toxikologie" können in der Summe die Entstehung einer "alters-bedingten" Macula – Degeneration (AMD) auslösen und beschleunigen.
    Spektrum der Augenheilkunde 08/2009; 23(4):240-248. DOI:10.1007/s00717-009-0340-y · 0.18 Impact Factor

Show more